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Abstract  
Background: The contribution of measurable immunological/inflammatory parameters to lung cancer 
development remains unclear, particularly among never-smokers. We investigated the relationship 
between total and differential white blood cell (WBC) counts and incident lung cancer risk overall and 
among subgroups defined by smoking status and sex in the United Kingdom (UK).  
Methods: We evaluated 424,407 adults aged 37-73 years from the UK Biobank. Questionnaires, physical 
measurements, and blood were administered/collected at baseline in 2006-2010. Complete blood cell 
counts were measured using standard methods. Lung cancer diagnoses and histological classifications 
were obtained from cancer registries. Multivariable Cox regression models were used to estimate the 
hazard ratio (HR) and 95% confidence intervals (CI) of incident lung cancer in relation to quartiles (Q) of 
total WBC and subtype-specific counts, with Q1 as the reference.  
Results: There were 1,493 incident cases diagnosed over an average 7-year follow-up. Overall, the 
highest quartile of total WBC count was significantly associated with elevated lung cancer risk 
(HRQ4=1.67, 95% CI:1.41-1.98). Among women, increased risks were found in current-smokers 
(ncases/n=244/19,464, HRQ4=2.15, 95% CI:1.46-3.16), former-smokers (ncases/n=280/69,198, HRQ4=1.75, 
95% CI:1.24-2.47), and never-smokers without environmental tobacco smoke exposure 
(ncases/n=108/111,294, HRQ4=1.93, 95% CI:1.11-3.35). Among men, stronger associations were identified 
in current-smokers (ncases/n=329/22,934, HRQ4=2.95, 95% CI:2.04-4.26) and former-smokers (ncases/n= 
358/71,616, HRQ4=2.38, 95% CI:1.74-3.27) but not in never-smokers. Findings were similar for lung 
adenocarcinoma and squamous cell carcinoma and were driven primarily by elevated neutrophil fractions. 
Conclusions: Elevated WBCs could potentially be one of many important markers for increased lung 
cancer risk, especially among never-smoking women and ever-smoking men.  
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Background 
Lung cancer is one of the most common malignancies in the western world with over 312,000 newly 
diagnosed cases every year in the European Union (E.U.) [1] and an estimated 234,030 in the United 
States (U.S.) in 2018 [2]. Lung cancer has an estimated five-year survival rate of only 18.6% due to 
diagnoses at late stages [2] and care for lung cancer patients constitutes a substantial economic burden in 
both the E.U. and U.S.[3, 4]. Identifying disease mechanism and risk factors in at-risk groups is crucial 
for devising population-level interventions. 
Elevated white blood cell (WBC) counts and immune markers have been associated with lung cancer in 
prospective cohort studies, suggesting a role for immune/inflammatory processes in lung cancer 
pathogenesis [5-12]. However, gaps in knowledge remain. In particular, the association between elevated 
WBC counts and lung cancer risk has not been extensively investigated among never-smokers due to 
challenges in accruing cases in western populations [12]. Lung cancer is largely considered to be driven 
by smoking [13] in western countries. However, it remains a notable malignancy among never-smokers 
[14, 15] with estimated incidence rates of 14.4-20.8 cases per 100,000 person-years for never-smoking 
women and 4.8-13.7 per 100,000 person-years for never-smoking men [16, 17]. Differences in 
immunologic/inflammatory parameters such as WBC counts among these subgroups could contribute to 
the varying rates. Furthermore, previous epidemiologic studies reported findings for total WBC counts, 
but not by WBC subtypes that could differentially influence risk. Additionally, previous studies did not 
consider different histological subtypes of lung cancer (i.e., adenocarcinoma and squamous cell 
carcinoma (SCC)), which have different risk factors and pathogenesis; therefore, deeper investigation 
could provide insight into disease etiology.  
To investigate the relationships between total and differential WBC counts and incident lung cancer risk 
overall and among subgroups defined by smoking status and sex, we analyzed data from the United 
Kingdom (UK) Biobank, a prospective cohort study of over half a million adults. This investigation  
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expands upon previous studies by including measurements of WBC subtypes and assessment of lung 
cancer histology, which could provide deeper understanding of the role key immunological/inflammatory 
processes play in lung cancer development.  
Methods 
Study Design 
The study design and data access procedures of the UK Biobank have been described elsewhere 
(http://www.ukbiobank.ac.uk/) [18, 19]. Briefly, the target population was adults aged 40-69 years who 
resided within 40 km of 22 assessment centers across the UK [18]. Of the 9.2 million individuals 
registered in the UK’s National Health Service (NHS) who were mailed invitations, 503,317 (5.5%) 
visited the assessment centers in 2006-2010 [19]. These volunteers received physical examinations, 
provided biological samples including 40-50 mL of whole blood, and were administered touchscreen 
questionnaires. Data from 502,616 participants were initially available for our analysis. After applying the 
exclusion criteria and data cleaning as specified in Figure 1, the final analytic sample size was 424,407 
participants.  
The UK Biobank study was approved by the National Information Governance Board for Health and 
Social Care and the NHS North West Multicenter Research Ethics Committee. Electronic informed 
consent was obtained from all volunteer participants [18, 19]. 
WBC counts 
WBCs and their subtypes (i.e., lymphocytes, neutrophils, monocytes, eosinophils, and basophils) were 
measured in whole blood obtained at baseline as described online (http://www.ukbiobank.ac.uk/). 
Complete blood cell counts (cells/L) were measured using a Coulter LH 750 System (Beckman Coulter) 
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as per manufacturer’s procedures. Measures of reliability/reproducibility for WBC counts are described in 
Appendix 1.  
Lung Cancer Ascertainment 
Cancer diagnoses were provided to UK Biobank by the Health and Social Care Information Centre 
(HSCIC) and the NHS Central Register (NHSCR) (http://www.ukiacr.org/). Lung cancer diagnosis was 
defined by International Classification of Diseases 10th revision (ICD-10 codes) C34.0-C34.9. ICD-O-3 
code 8140 was used to define adenocarcinoma, while 8052, 8084, 8073, and 8083 were used for SCC. 
Cohort Follow-up 
Follow-up time was counted from the date of visit to the assessment center until the date of incident lung 
cancer diagnosis, death, or administrative censoring (i.e., January 31, 2016 for England and Wales and 
November 30, 2015 for Scotland), whichever came first. The NHS Information Centre and the NHS 
Central Register Scotland provided vital status, along with date and primary underlying cause of death. 
Statistical Analysis 
A detailed 25-level smoking variable was created as previously described [20] (Table 1). A 6-level 
variable for alcohol intake was utilized (never, former, current-infrequent (<3 times per month), current-
modest (<1 drink per day), current-frequent (≥1 to ≤3 drinks per day), and current-heavy (>3 drinks per 
day)) [21]. Body mass index (BMI, kg/m2) was categorized as <18.5, ≥18.5-<25.0, ≥25.0-<30.0, ≥30.0-
<35.0, and ≥35.0 kg/m2. Self-reported race/ethnicity/ancestry was categorized as European, Asian (East 
and South), Black (African ancestry), mixed, other, and missing/unknown/no answer. Less than 9% of the 
cohort lacked data on any single covariate. Indicator variables were created for missing data among 
categorical variables, while mean imputation was used to account for missing Townsend Deprivation 
Index (continuous). 
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Multivariable Cox regression models were used to estimate cause-specific hazard ratios (HR) and 95% 
confidence intervals (CI) of incident lung cancer diagnosis and its histological subtypes, in relation to 
quartiles (Q) of total WBC, lymphocyte, neutrophil, monocyte, basophil, and eosinophil counts in 
separate  analyses. The lowest quartile (Q1) was the reference group. We also analyzed neutrophil-to-
lymphocyte ratio (NLR). Those who died or were administratively censored before the outcome across 
the follow-up were not counted as outcomes. We adjusted for detailed smoking [20] (reference: never-
smokers), race/ethnicity/ancestry (reference: European), study assessment center, age at recruitment 
(continuous), sex (reference: male), BMI (reference: ≥18.5-<25.0 kg/m2), Townsend Deprivation Index 
(continuous), and alcohol intake (reference: never-drinker) [21].  We also considered environmental 
tobacco smoke (ETS) exposure and ever having a self-reported respiratory disease as covariates. 
However, adjusting for these variables did not considerably change the estimates; therefore, results from 
the more parsimonious model are presented. Follow-up time (days) was used as the underlying timescale. 
Trends were tested by analyzing the WBC categories as ordinal. Supremum tests were used to assess 
proportional hazards assumptions. 
The analyses were further stratified by a sex-smoking combination variable (i.e., never-, former-, and 
current-smoking women and men). The stratified analyses did not include cigar and pipe smokers. We 
also conducted a sensitivity analysis restricting the overall study population to European participants 
(94%) to assess the influence of race/ethnicity/ancestry. For the main stratified analyses, we based the 
quartiles of WBC count on the distribution of each subgroup because of previously established differences 
by sex [22, 23] and smoking [24-27], as well as race/ethnicity/ancestry [22, 23]. We conducted sensitivity 
analyses of the subgroups using common WBC quartile cutoffs from the overall analyses. Multiplicative 
effect modification of WBC counts by a sex-smoking combination variable and age was assessed using 
interaction terms. The interaction analyses with sex-smoking were conducted using the overall WBC 
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quartile cutoffs. In separate analyses, never-smoking women and men were restricted to those not exposed 
to ETS (<1 hour/week) to mitigate the influence of secondhand smoke.  
To assess the potential influence of underlying disease bias on WBC counts, we conducted separate 
analyses in which cases diagnosed before 2 years of follow-up were excluded as outcomes. In additional 
sensitivity analyses, we restricted the overall study population to: 1) those who reported not being 
exposed to ETS (<1 hour/week), 2) those who reported never having a history of respiratory diseases, and 
3) those <67 years of age at baseline because of potentially reduced ability to produce higher WBC counts 
among the oldest participants [28]. All stratified, subgroup, and sensitivity analyses were defined a priori 
with a hypothesis-driven approach. 
Two-sided P-values <0.05 were considered noteworthy. We applied an extremely conservative Bonferroni 
corrected threshold of α=1.7x10-4 to account for multiple comparisons (α=0.05/295 total tests across all 
analyses).  
Results 
Study population characteristics 
Among the participants with WBC data, we analyzed 1,493 incident lung cancer cases over a maximum 
10-year follow-up (7-year average). The average age at recruitment was 56.2±8.1 SD years. The 
cumulative person-time was 2.94 million person-years (py) and the average age of lung cancer diagnosis 
among cases was 65.2±6.0 SD years. There were 562 confirmed lung adenocarcinomas and 285 
confirmed lung SCC. Differences in WBC counts between categories of various population characteristics 
at baseline are shown in Table 1.  
Total and differential WBC count and lung cancer risk 
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Overall, we observed a positive trend in lung cancer risk with increasing WBC count (p-trend=1.4x10-12). 
Compared to the lowest quartile of total WBC, the highest quartile was associated with an estimated 1.67 
(95% CI: 1.41-1.98, p=4.4x10-9) times increased risk (Table 2). This relationship was primarily driven by 
an association with neutrophils (HRQ4=1.57, 95% CI: 1.33-1.84, p=7.1x10
-8). There was also evidence for 
a marginal positive association between monocytes and lung cancer risk (HRQ4=1.17, 95% CI: 1.00-1.36, 
p=0.04); however, monocytes comprise only a small fraction of WBC and displayed narrow statistical 
variability. There was no evidence for interactions between quartiles of WBC count and age 
(pinteractions=0.63, 0.79, 0.88 across quartiles).  
WBC count and lung cancer risk among subgroups defined by smoking status and sex 
Among the 232,528 never-smokers, the highest quartile of WBC count was associated with increased risk 
of lung cancer, compared to the lowest quartile (HRQ4=1.52, 95% CI: 1.03-2.25, p=0.03; HRQ3=1.00, 95% 
CI: 0.64-1.50, p=0.99; HRQ2=1.10, 95% CI: 0.75-1.62, p=0.63). 
Among women, risk estimates were elevated among never-smokers (HRQ4=1.82, 95% CI: 1.10-3.00, 
p=0.02), former-smokers (HRQ4=1.75, 95% CI: 1.24-2.47, p=1.4x10
-3) and current-smokers (HRQ4=2.15, 
95% CI: 1.46-3.16, p=1.0x10-4) (Table 3). Among never-smoking women, excluding those who were 
exposed to ETS nominally increased the risk estimate (HRQ4=1.93, 95% CI: 1.11-3.35, p=0.02) (Table 3).  
Among men, the associations were moderately stronger for former-smokers (HRQ4=2.38, 95% CI: 1.74-
3.27, p=6.3x10-8) and especially for current-smokers (HRQ4=2.95, 95% CI: 2.04-4.26, p=8.5x10
-9). 
However, noteworthy associations were not observed for never-smoking men, with or without excluding 
those exposed to ETS (Table 3).  
Based on the apparent differences among the stratified risk estimates, we tested for multiplicative 
interactions between WBC counts and the smoking-sex combination variable. Compared to never-
smoking men, there was no evidence of effect modification for never-smoking women (p-
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interaction=0.22); however, there was evidence among former-smoking women (p-interaction=0.04), 
current smoking women (p-interaction=0.02), former-smoking men (p-interaction=2.4x10-3) and current 
smoking men (p-interaction=7.0x10-4).  
We also analyzed current-smoking women and men stratified by smoking intensity. The associations 
between WBC count and lung cancer risk were slightly stronger among those who currently smoke <20 
cigarettes/day compared with ≥20 cigarettes/day (Women: HRQ4=2.55, 95% CI: 1.17-5.57, p=0.02 vs. 
HRQ4=0.60, 95% CI: 0.26-1.40, p=0.24; Men: HRQ4=5.23, 95% CI: 2.12-12.90, p=3.2x10
-4 vs. 
HRQ4=1.83, 95% CI: 0.67-4.98, p=0.24). There was evidence for effect modification among women (p-
interaction=0.03), but not among men (p-interaction=0.11). 
WBC count, lung adenocarcinoma, and squamous cell carcinoma 
We also analyzed histological subtypes of lung cancer and found similar trends for lung adenocarcinoma 
and SCC (Table 2) relative to the overall analyses. Notably, there were similar risk estimates for the 
analyses of WBC count and lung adenocarcinoma (HRQ4=1.68, 95% CI: 1.28-2.22, p=2.0x10
-4) and SCC 
(HRQ4=1.55, 95% CI: 1.04-2.29, p=0.03), compared to overall lung cancer. Additionally, there was 
evidence for an association between lymphocytes and SCC (HRQ4=1.46, 95% CI: 1.03-2.06, p=0.03). 
Although the number of cases was small, we also stratified the analyses of lung adenocarcinoma by 
smoking status and sex. Similar patterns were found as the analyses for overall lung cancer 
(Supplementary Table 1). 
Additional analyses 
In the 2-year lagged analyses, increased total WBC counts remained associated with increased lung 
cancer risk (Supplementary Table 2). Additionally, comparable results were found when restricting to 
Europeans (Supplementary Table 3). Furthermore, excluding those who self-reported ever having a 
respiratory disease or ETS exposure, as well as excluding participants who were ≥67 years old at 
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recruitment from the analyses did not influence the results (data not shown). In the subgroup analyses, 
using subgroup-specific or overall quartile cut points did not affect the findings  (Supplementary Tables 4 
and 5). Lastly, we found that increasing NLR was associated with increased lung cancer risk overall 
(HRper 1.0 increase=1.14, 95% CI: 1.09-1.19, p=8.3x10
-9), among never- and current-smoking women, and 
ever-smoking men (Supplementary Table 6) 
Discussion 
In a prospective cohort study of nearly half a million adults from the UK, we observed that elevated total 
WBC count was associated with increased risk of developing lung cancer. The risk estimates among 
current-, former-, and never-smoking women were comparable to the overall analyses, while the 
associations were stronger among former- and current-smoking men. Similar elevated risk estimates were 
found for the two major subtypes of lung cancer, adenocarcinoma and SCC. The associations between 
WBC counts and lung cancer were primarily driven by elevated neutrophil counts, a key component of 
innate immunity which constitutes 40-60% of WBCs. Similar to previous studies [29-31], we found that 
increasing NLR was associated with increased risk. Notably, our study is one of the first of sufficient 
power to investigate the relationship between WBC count and lung cancer risk among never-smoking 
women, an under-studied group. Our findings are consistent and robust across sensitivity analyses. 
In the stratified analyses, there was evidence for a stronger relationship between WBC count and lung 
cancer risk among smokers. Additionally, the associations were generally greater among men, with risk 
estimates being highest for current-smoking men. Among current cigarette smokers, most of the 
moderate-to-heavy smokers who smoked ≥20 cigarettes per day were men (61%), which could partially 
explain the findings. However, the stronger associations among men remained after performing the 
analyses among current-smokers adjusting for and stratified by smoking intensity. Notably, we found 
positive associations between WBC counts and lung cancer risk among never-smoking women but for not 
never-smoking men, which could be due to the smaller sample size for never-smoking men. Although 
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WBC counts could contribute to lung cancer development, lung carcinogenesis among never-smoking 
women is strongly linked to underlying driver mutations/pathways (e.g. EGFR mutations[32], EML4-
ALK fusions[33], ROS1 rearrangements[34]). 
Our findings are concordant with previous epidemiologic studies of WBC count and lung cancer 
development [9-12, 35] (Supplementary Table 7). An investigation in the Women’s Health Initiative 
(WHI) found positive associations between WBC count and lung cancer among post-menopausal women 
[12]. However, the WHI study did not detect an association among never-smoking women (estimates 
were not reported) [12]. Our study found a noteworthy association among never-smoking women that was 
marginally stronger when further restricting to those without ETS exposure. Several factors could have 
contributed to the discrepancies including statistical power and differences in analyses and the source 
populations. Notably, the age-range of the WHI participants (50-79 years) was higher than for the UK 
Biobank (37-73 years). Additionally, UK Biobank was a population-based cohort study, whereas the WHI 
combined randomized trials with an observational study, which could have introduced heterogeneity. 
Similar to our investigation, an analysis of three male cohort studies from the U.S. and U.K. found 
increased lung cancer incidence and mortality with elevated WBC [9]. Additionally, a cohort study of 
4,831 men and women from Wisconsin, USA found that those with elevated WBC counts over 6.4x109 
cells/L had nearly triple the risk compared to those under this threshold [10]. Further, the Blue Mountains 
Eye Study and the second National Health and Nutrition Examination Survey (NHANES II) found non-
significant positive associations between WBC count and lung cancer mortality [11, 35].  
The interrelationship between inflammation and lung cancer development is widely accepted [36]; 
however, underlying mechanisms remain unclear. Chronic inflammation of lung tissue caused by 
exposure to hazardous particulates could promote apoptosis and necrosis, which induces the release of 
reactive oxygen species. These genotoxic chemicals can cause deleterious changes to tumor suppressors 
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or proto-oncogenes with prolonged exposure. Indeed, various circulating immunological/inflammatory 
markers were significantly associated with lung cancer risk [6, 7].   
The role of lymphocytes is well-documented with respect to lung cancer prognosis, but their relationship 
with future risk is unclear. We did not detect associations between lymphocyte count and future risk of 
developing lung cancer. Rather, we found that the WBC-lung cancer association was driven by 
neutrophils. Taken together, these findings suggest that early changes to innate response could be more 
pertinent to future disease risk and etiology among cancer-free individuals, whereas cell-mediated 
immune response may be more reflective of cancer progression. Indeed, neutrophils are considered 
inflammatory “first responders” that have been shown in animal models to mediate clearance of early 
tumor cells [37], but can promote drive tumor progression [38].  In the few studies that found positive 
associations between NLR and future risk [29, 31], the exposure-response could have been related to 
increased neutrophils more so than changes in lymphocyte counts. 
This study has several strengths. First, the large sample size provided adequate statistical power to detect 
modest effects overall and stratified by smoking status and sex. Second, we had data on histological 
subtypes of lung cancer, providing greater insight into disease etiology. Third, lung cancer diagnoses were 
obtained from comprehensive government cancer registries linked to multiple sources. Fourth, we could 
establish temporality between WBC counts and lung cancer development with the prospective cohort 
study design. Lastly, we had extensive information on smoking, which allowed tight control of residual 
confounding from tobacco use.  
This study has limitations. We only had sufficient WBC data from a single baseline blood draw and 
therefore could not assess the influence of trajectories in WBC counts on lung cancer risk. We assumed 
that WBC count at baseline reflected levels in the etiologic window for lung carcinogenesis. WBC count 
varies in the short-term in response to infection and environmental exposures. Further, longitudinal 
studies have found U-shaped patterns in WBC counts over the lifecourse [39]. However, resting-state 
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WBC count at single timepoints have been shown in many studies to be associated with future risk of 
numerous chronic diseases and mortality [40-45].  
In summary, we found that increased total WBC count was associated with increased lung cancer risk. 
This relationship was primarily driven by neutrophil fractions, which are crucial components of innate 
immune response. The associations among current-, former-, and never-smoking women were comparable 
to the overall analyses, while stronger associations were found among former and current-smoking men. 
Notably, this was one of the few studies to report associations among never-smoking women. Our study 
provides further evidence that immunological/inflammatory processes contribute to lung carcinogenesis, 
particularly among never-smoking women and ever-smoking men. 
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Table 1:  White Blood Cell Counts by Population Characteristics in the UK Biobank (n=424,407)       
    
Total White Blood Cell Count (109 cells/L) 
 
    n, subjects  % Mean SD    
Overall  424,407 100.0 6.88  1.87   
Age at recruitment, years               
37-46   68,228 16.1 6.87 1.83    
47-56   130,826 30.8 6.80 1.83     
57-66   183,107 43.1 6.89 1.89     
67-76   42,246 10.0 7.08 1.94     
Genetic Sex               
Female   224,139 52.8 6.86 1.83    
Male   200,268 47.2 6.90 1.91     
Self-Reported Race/Ethnicity/Ancestry               
European   399,302 94.1 6.89 1.87    
Black, African   6,694 1.6 5.80 1.65     
Asian, East and South   9,955 2.3 7.20 1.78     
Mixed   2,522 0.6 7.06 1.85     
Other   3,904 0.9 6.81 2.06    
Unknown, missing, no answer   2,030 0.5 6.91 1.88    
Body Mass Index, BMI, kg/m2              
 <18.5    1,908 0.4 6.61 2.56    
≥18.5 - <25.0   132,902 31.3 6.56 1.87     
≥25.0 - <30.0   179,584 42.3 6.84 1.82     
≥30.0 - <35.0   73,931 17.4 7.20 1.79     
≥35.0   28,647 6.7 7.72 1.89     
Missing   7,435 1.8 7.14 2.03     
Townsend Deprivation Index               
Lower (< median of -2.13)   212,813 50.1 6.77 1.81    
Upper (≥ median of -2.13)   211,594 49.9 6.99 1.92    
Smoking status and history              
Never   232,528 54.8 6.67 1.76    
Current occasional smoker, smoked <100 cigarettes in lifetime   538 0.1 6.89 1.79    
Current occasional smoker, smoked ≥100 cigarettes in lifetime   6,656 1.6 6.92 1.74     
Current occasional smoker, smoked cigars or pipes daily in past   265 0.1 7.27 1.94     
Current occasional smoker, smoked cigarettes daily in past   2,476 0.6 7.32 1.96     
Current occasional smoker, smoked cigarettes daily in past, ≥20 cigarettes/day   1,436 0.3 7.60 1.95     
Current cigar pipe smoker, former cigarette smoker   1,569 0.4 8.12 2.06     
Current cigar pipe smoker, not former cigarette smoker   744 0.2 7.56 1.97     
Current cigarette smoker, <10 cigarettes/day   6,099 1.4 7.68 1.99     
Current cigarette smoker, ≥10 to <20 cigarettes/day   12,863 3.0 8.47 2.10     
Current cigarette smoker, ≥20 to <40 cigarettes/day   10,665 2.5 8.89 2.20     
Current cigarette smoker, ≥40 cigarettes/day   721 0.2 9.08 2.25     
Former occasional cigarette smoker, smoked <100 cigarettes in lifetime   6,836 1.6 6.69 1.68     
Former occasional cigarette smoker, smoked ≥100 cigarettes in lifetime   38,349 9.0 6.68 1.71     
Former occasional cigarette smoker, lifetime smoking unknown   3,012 0.7 6.67 1.66     
Former daily cigar pipe smoker   4,215 1.0 6.98 1.79     
Former cigarette smoker, <20 cigarettes/day, quit <1 year ago   907 0.2 7.39 1.92     
Former cigarette smoker, ≥20 cigarettes/day, quit <1 year ago   1,058 0.2 7.70 1.91     
Former cigarette smoker, <20 cigarettes/day, quit ≥1-<5 year ago   4,777 1.1 7.00 1.77     
Former cigarette smoker, ≥20 cigarettes/day, quit ≥1-<5 year ago   5,886 1.4 7.34 1.91     
Former cigarette smoker, <20 cigarettes/day, quit ≥5-<10 year ago   5,045 1.2 6.90 1.73     
Former cigarette smoker, ≥20 cigarettes/day, quit ≥5-<10 year ago   7,040 1.7 7.19 1.87     
Former cigarette smoker, <20 cigarettes/day, quit ≥10-<20 year ago   8,943 2.1 6.79 1.69     
Former cigarette smoker, ≥20 cigarettes/day, quit ≥10-<20 year ago   12,256 2.9 7.04 1.90     
Former cigarette smoker, <20 cigarettes/day, quit ≥20 year ago   20,302 4.8 6.66 1.78     
Former cigarette smoker, <20/day (LT 1/day), quit ≥20 year ago   25,329 6.0 6.87 1.79     
Other/unknown/missing   3,892 0.9 7.23 2.34     
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Self-reported environmental tobacco smoke (ETS) exposure at home or outside             
Unexposed (<1 hour/week)   343,646 81.0 6.89 1.88    
Exposed (≥1 hour/week)   80,761 19.0 6.84 1.81    
History of respiratory disease (i.e., asthma, chronic obstructive pulmonary disease, 
emphysema, bronchitis, bronchiectasis, interstitial lung disease, asbestosis, 
pulmonary fibrosis, other respiratory problems)               
No   371,250 87.5 6.83 1.85    
Yes   53,157 12.5 7.20 1.99    
Alcohol Consumption              
Never   18,460 4.3 7.00 2.01    
Former   14,862 3.5 7.22 2.08     
Current Infrequent, <3 times/month   94,731 22.3 7.06 1.98     
Current Modest, <1 drink/day   105,131 24.8 6.78 1.84     
Current Frequent, ≥1-≤3 drinks/day   153,623 36.2 6.76 1.73     
Current Heavy, >3 drinks/day   36,404 8.6 6.96 1.98     
Missing   1,196 0.3 7.09 1.95     
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Table 2: Associations between total and differential white blood cell counts and lung cancer risk in the UK Biobank (n=424,407) 
      I) Overall lung cancer (n=1,493)   II) Lung adenocarcinoma (n=562)   III) Lung squamous cell carcinoma (n=285) 
Quartile 
Cell counts, 109 
cells/L 
No. of 
incident 
cases 
HR 
95% CI 
Lower 
95% CI 
Upper 
p-value     
No. of 
incident 
cases 
HR 
95% CI 
Lower 
95% CI 
Upper 
p-value     
No. of 
incident 
cases 
HR 
95% CI 
Lower 
95% CI 
Upper 
p-value   
Total WBC                                         
  1 ≤5.64 188 1.00           76 1.00           34 1.00         
  2 >5.64-≤6.66 242 1.04 0.86 1.26 0.68     116 1.30 0.97 1.73 0.08     34 0.74 0.46 1.19 0.21   
  3 >6.66-≤7.86 330 1.13 0.94 1.35 0.20     121 1.13 0.85 1.52 0.40     56 0.89 0.58 1.38 0.61   
  4 >7.86 733 1.67 1.41 1.98 4.4E-09 **   249 1.68 1.28 2.22 2.0E-04 *   161 1.55 1.04 2.29 0.03 * 
            p-trend 1.4E-12 **         p-trend 2.8E-04 *         p-trend 4.7E-04 * 
Lymphocytes                                         
  1 ≤1.52 297 1.00           127 1.00           51 1.00         
  2 >1.52-≤1.89 280 0.91 0.77 1.07 0.26     109 0.83 0.64 1.07 0.14     54 1.02 0.69 1.50 0.92   
  3 >1.89-≤2.30 389 1.00 0.86 1.17 0.98     143 0.89 0.69 1.13 0.32     58 0.86 0.58 1.25 0.42   
  4 >2.30 524 1.13 0.97 1.31 0.12     181 0.95 0.75 1.21 0.68     121 1.46 1.03 2.06 0.03 * 
            p-trend 0.04 *         p-trend 0.91           p-trend 0.03 * 
Neutrophils                                         
  1 ≤3.27 210 1.00           95 1.00           36 1.00         
  2 >3.27-≤4.02 232 0.87 0.72 1.05 0.15     82 0.72 0.54 0.97 0.03 *   30 0.60 0.37 0.97 0.04 * 
  3 >4.02-≤4.97 337 1.06 0.89 1.26 0.52     143 1.10 0.85 1.44 0.47     66 1.02 0.68 1.55 0.91   
  4 >4.97 711 1.57 1.33 1.84 7.1E-08 **   240 1.40 1.09 1.81 0.01 *   152 1.51 1.03 2.21 0.04 * 
            p-trend 2.9E-13 **         p-trend 6.3E-05 **         p-trend 1.4E-04 ** 
Basophils                                         
  1 0 487 1.00           178 1.00           89 1.00         
  2 >0-≤0.02 232 0.84 0.69 1.01 0.06     111 0.90 0.67 1.21 0.48     26 0.54 0.33 0.89 0.01 * 
  3 >0.02-<0.04 268 0.86 0.71 1.03 0.10     112 0.83 0.62 1.12 0.23     63 1.07 0.71 1.61 0.74   
  4 ≥0.04 503 1.12 0.98 1.30 0.11     159 0.91 0.71 1.17 0.47     106 1.21 0.88 1.68 0.24   
            p-trend 0.02 *         p-trend 0.52           p-trend 0.02 * 
Monocytes                                         
  1 ≤0.37 277 1.00           131 1.00           35 1.00         
  2 >0.37-≤0.45 285 0.95 0.81 1.12 0.56     106 0.79 0.61 1.02 0.08     56 1.38 0.90 2.11 0.14   
  3 >0.45-≤0.57 335 0.91 0.77 1.07 0.25     135 0.84 0.66 1.08 0.17     65 1.20 0.80 1.82 0.38   
  4 >0.57 592 1.17 1.00 1.36 0.04 *   188 0.92 0.73 1.17 0.50     128 1.51 1.03 2.22 0.04 * 
            p-trend 0.02 *         p-trend 0.73           p-trend 0.06   
Eosinophils                                         
  1 ≤0.10 511 1.00           206 1.00           83 1.00         
  2 >0.10-≤0.14 150 1.01 0.84 1.22 0.94     69 1.08 0.81 1.43 0.61     29 1.14 0.74 1.77 0.56   
  3 >0.14-≤0.21 378 0.93 0.81 1.06 0.26     124 0.79 0.64 1.00 0.04 *   79 1.08 0.79 1.47 0.64   
  4 >0.21 408 0.91 0.79 1.04 0.15     143 0.84 0.68 1.05 0.12     83 0.97 0.71 1.33 0.85   
            p-trend 0.11           p-trend 0.04 *         p-trend 0.86   
*p-values <0.05.  
**p-values below a Bonferroni corrected alpha threshold of 1.7x10-4.  
Quartiles of WBC counts were based on the distribution of the overall study population. Cox regression models were adjusted for age, sex, BMI, race/ethnicity/ancestry, assessment center, 
detailed smoking status/intensity/history, alcohol consumption, and Townsend Deprivation Index as surrogate for socioeconomic status. Abbreviations: Hazard Ratio (HR), Confidence 
Interval (CI), White Blood Cells (WBC). Discrepancy in counts due to missing blood cell data. 
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Table 3: Associations between total white blood cell counts and overall lung cancer risk in the UK Biobank by cigarette smoking status and sex 
I) Women               II) Men               
Smoking status Quartile, WBC 
count, 109 
cells/L 
No. of 
incident 
cases 
HR 95% CI 
Lower 
95% CI 
Upper 
p-value   Smoking status Quartile, WBC 
count, 109 
cells/L 
No. of 
incident 
cases 
HR 95% CI 
Lower 
95% CI 
Upper 
p-value   
Never-smokers,  1, ≤5.55 26 1.00         Never-smokers, 1, ≤5.50 22 1.00         
n=134,209 2, >5.55-≤6.51 33 1.27 0.76 2.13 0.37   n=98,319 2, >5.50-≤6.41 17 0.77 0.41 1.46 0.42   
 3, >6.51-≤7.67 27 1.09 0.64 1.88 0.75    3, >6.41-≤7.50 15 0.63 0.32 1.22 0.17   
  4, >7.67 41 1.82 1.10 3.00 0.02 *   4, >7.50 24 0.96 0.53 1.75 0.90   
          p-trend 0.04 *           p-trend 0.81   
Never-smokers, 
No ETS exposure, 
1, ≤5.55 21 1.00         Never-smokers, 
No ETS exposure, 
1, ≤5.50 15 1.00         
n=111,294 2, >5.55-≤6.51 30 1.43 0.82 2.49 0.21   n=75,918 2, >5.50-≤6.41 14 0.89 0.43 1.85 0.75   
 3, >6.51-≤7.67 22 1.11 0.61 2.03 0.74    3, >6.41-≤7.50 13 0.74 0.35 1.58 0.44   
  4, >7.67 35 1.93 1.11 3.35 0.02 *   4, >7.50 20 1.09 0.55 2.16 0.81   
          p-trend 0.05 *           p-trend 0.87   
Former-smokers, 1, ≤5.60 52 1.00         Former-smokers, 1, ≤5.70 55 1.00         
n=69,198 2, >5.60-≤6.60 58 1.05 0.72 1.53 0.79   n=71,616 2, >5.70-≤6.70 65 1.11 0.77 1.59 0.59   
 3, >6.60-≤7.73 71 1.31 0.91 1.88 0.14    3, >6.70-≤7.82 82 1.33 0.94 1.88 0.11   
  4, >7.73 99 1.75 1.24 2.47 1.4E-03 *   4, >7.82 156 2.38 1.74 3.27 6.3E-08 ** 
          p-trend 3.6E-04 *           p-trend 7.7E-10 ** 
Current-smokers, 1, ≤6.60 38 1.00         Current-smokers, 1, ≤6.58 37 1.00         
n=19,464 2, >6.60-≤7.85 51 1.25 0.82 1.90 0.30   n=22,934 2, >6.58-≤7.90 62 1.37 0.91 2.06 0.13   
 3, >7.85-≤9.30 63 1.45 0.96 2.17 0.08    3, >7.90-≤9.39 93 2.04 1.39 3.00 2.6E-04 * 
  4, >9.30 92 2.15 1.46 3.16 1.0E-04 **   4, >9.39 137 2.95 2.04 4.26 8.5E-09 ** 
          p-trend 3.3E-05 **           p-trend 1.6E-11 ** 
*p-values <0.05.  
**p-values below a Bonferroni corrected alpha threshold of 1.7x10-4.  
The analyses did not include cigar and pipe smokers. Cox regression models were adjusted for age, BMI, race/ethnicity/ancestry, assessment center, alcohol consumption, and Townsend 
Deprivation Index as a surrogate for socioeconomic status. Discrepancy in counts due to missing blood cell data. WBC quartiles were based on the distribution of each sex-smoking 
subgroup. Abbreviations: Hazard Ratio (HR), Confidence Interval (CI), White Blood Cells (WBCs), Environmental Tobacco Smoke (ETS). We tested multiplicative effect modification of 
WBC counts by the smoking-sex combination variable using interaction terms. Compared to never smoking men, there was no evidence of effect modification for never-smoking women (p-
interaction=0.22); however, there was evidence among former-smoking women (p-interaction=0.04), current smoking women (p-interaction=0.02), former-smoking men (p-
interaction=2.4x10-3) and current smoking men (p-interaction=7.0x10-4).    
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Figure 1: Flow chart of baseline exclusion criteria and the prospective follow-up. Abbreviations: White Blood Cell (WBC) 
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• (n=188) incident lung 
cancer cases 
(outcome)
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• (n=242) incident lung 
cancer cases 
(outcome)
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• (n=330) incident lung 
cancer cases 
(outcome)
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Figure 1:Flow chart of baseline exclusion criteria and the prospective follow-up. Abbreviations: White
Blood Cell (WBC)
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